Effect of Insurance Type on Stage at Presentation, Surgical Approach, Tumor Recurrence and Cancer-Specific Survival in Resectable Non-Small Lung Cancer Patients

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Thailand IHPPi. Regional Differences in Burden of Disease in Thailand. Nontaburi: The graphico system limied; 2012.
   Google Scholar
• Raz DJ, Zell JA, Ou SI, et al. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132(1):193–199. doi:10.1378/chest.06-309617505036
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the Forthcoming (Eighth) Edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.00926762738
   PubMed Web of Science ®Google Scholar
• Health Insurance System Research Office (HISRO). Thailand’s Universal Coverage Scheme: Achievements and Challenges. An Independent Assessment of the First 10 Years (2001–2010). Nonthaburi, Thailand: HISRO; 2012 Available from: http://www.hisro.or.th/main/modules/research/attachgovernance/177/Full-text.pdf. Accessed 54, 2020.
   Google Scholar
• Groth SS, Al-Refaie WB, Zhong W, et al. Effect of insurance status on the surgical treatment of early-stage non-small cell lung cancer. Ann Thorac Surg. 2013;95(4):1221–1226. doi:10.1016/j.athoracsur.2012.10.07923415239
   PubMed Web of Science ®Google Scholar
• Hardy D, Liu -C-C, Xia R, et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer. 2009;115(10):2199–2211. doi:10.1002/cncr.2424819365824
   PubMed Web of Science ®Google Scholar
• Walker GV, Grant SR, Guadagnolo BA, et al. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol. 2014;32(28):3118–3125. doi:10.1200/JCO.2014.55.625825092774
   PubMed Web of Science ®Google Scholar
• Tantraworasin A, Taioli E, Liu B, et al. The influence of insurance type on stage at presentation, treatment, and survival between Asian American and non-Hispanic White lung cancer patients. Cancer Med. 2018;7(5):1612–1629. doi:10.1002/cam4.133129575647
   PubMed Web of Science ®Google Scholar
• Elchoufani SE, Efird JT, O’Neal WT, et al. The relation of race and type of health insurance to long-term risk of mortality among lung cancer patients in rural Eastern North Carolina. NC Med J. 2013;74(6):464–469.
   Google Scholar
• Efird JT, Landrine H, Shiue KY, et al. Race, insurance type, and stage of presentation among lung cancer patients. SpringerPlus. 2014;3(1):710. doi:10.1186/2193-1801-3-71025674451
   PubMedGoogle Scholar
• Sommers BD, Gawande AA, Baicker K. Health insurance coverage and health - what the recent evidence tells us. N Engl J Med. 2017;377(6):586–593. doi:10.1056/NEJMsb170664528636831
   PubMed Web of Science ®Google Scholar
• Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–e313S. doi:10.1378/chest.12-235923649443
   PubMed Web of Science ®Google Scholar
• Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10(4):585–598. doi:10.1002/sim.47801004102057657
   PubMed Web of Science ®Google Scholar
• Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117(2):294–299. doi:10.1002/ijc.2118315900604
   PubMed Web of Science ®Google Scholar
• Field R, Smith B, Platz C, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105–1107. doi:10.1093/jnci/djh18915265973
   PubMedGoogle Scholar
• Li X, Zhou Q, Wang X, et al. The effect of low insurance reimbursement on quality of care for non-small cell lung cancer in China: a comprehensive study covering diagnosis, treatment, and outcomes. BMC Cancer. 2018;18(1):683. doi:10.1186/s12885-018-4608-y29940893
   PubMed Web of Science ®Google Scholar
• Stokes SM, Wakeam E, Swords DS, et al. Impact of insurance status on receipt of definitive surgical therapy and posttreatment outcomes in early stage lung cancer. Surgery. 2018;164(6):1287–1293. doi:10.1016/j.surg.2018.07.02030170821
   PubMed Web of Science ®Google Scholar
• Ou SHI, Zell JA, Ziogas A, et al. Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer. 2008;112(9):2011–2020. doi:10.1002/cncr.2339718361399
   PubMed Web of Science ®Google Scholar
• Yorio JT, Yan J, Xie Y, et al. Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center. Clin Lung Cancer. 2012;13(6):448–457. doi:10.1016/j.cllc.2012.03.00222512997
   PubMed Web of Science ®Google Scholar
• Slatore CG, Au DH, Gould MK. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes. Am J Respir Crit Care Med. 2010;182(9):1195–1205. doi:10.1164/rccm.2009-038ST21041563
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Ohde Y, Wakuda K, et al. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;80(3):609–614. doi:10.1007/s00280-017-3400-z28761967
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244–2250. doi:10.1200/JCO.2018.78.799429864379
   PubMed Web of Science ®Google Scholar
• Esnaola NF, Gebregziabher M, Knott K, et al. Underuse of surgical resection for localized, non–small cell lung cancer among whites and African Americans in South Carolina. Ann Thorac Surg. 2008;86(1):220–227. doi:10.1016/j.athoracsur.2008.02.07218573427
   PubMed Web of Science ®Google Scholar
• Cheung MC, Hamilton K, Sherman R, et al. Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients. Ann Surg Oncol. 2009;16(1):3–13. doi:10.1245/s10434-008-0025-918600379
   PubMed Web of Science ®Google Scholar
• Rueth NM, Andrade RS. Is VATS lobectomy better: perioperatively, biologically and oncologically? Ann Thorac Surg. 2010;89(6):S2107–11. doi:10.1016/j.athoracsur.2010.03.02020493991
   PubMed Web of Science ®Google Scholar
• Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg. 2010;139(4):976–81; discussion 81–3. doi:10.1016/j.jtcvs.2009.11.059
   Web of Science ®Google Scholar
• Higuchi M, Yaginuma H, Yonechi A, et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage IA non-small cell lung cancer. J Cardiothorac Surg. 2014;9:88. doi:10.1186/1749-8090-9-8824886655
   PubMed Web of Science ®Google Scholar
• Tomaszek SC, Cassivi SD, Shen KR, et al. Clinical outcomes of video-assisted thoracoscopic lobectomy. Mayo Clinic Proceedings; 2009: Elsevier.
   Google Scholar